pre-seed
Stage
1
Investors
About
Kasvu Therapeutics develops first-in-class small molecule neuroplastogens that target the TrkB receptor to improve neuronal plasticity for the treatment of neuropsychiatric and neurodegenerative diseases.
Explore Kasvu Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.